MedTrace Logo

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

NCT02210663 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-05-07

No results posted yet for this study

Summary

This is a Phase 1 study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of single agent Veliparib in Japanese subjects with advanced solid tumors.

Conditions

Interventions

DRUG

veliparib (ABT-888)

Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.

Sponsors & Collaborators

Principal Investigators

  • Hideyuki Hashiba, BS · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-01-31
Completion
2016-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02210663 on ClinicalTrials.gov